SCHEMBL11973643

SCHEMBL11973643

Cc1cc([N+](=O)[O-])c2ncccc2c1C

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 12/20 0.63
KMT2A Q03164 12/20 0.63
SMN1; SMN2 Q16637 4/20 0.63
MAPT P10636 12/20 0.55
ALDH1A1 P00352 10/20 0.55
L3MBTL1 Q9Y468 6/20 0.55
KDM4E B2RXH2 6/20 0.55
LMNA P02545 4/20 0.55
CTSB P07858 2/20 0.55
IDO1 P14902 2/20 0.55
TDO2 P48775 2/20 0.55
GAA P10253 1/20 0.55
CRHBP P24387 1/20 0.53
CRHR2 Q13324 1/20 0.53
NPSR1 Q6W5P4 1/20 0.53
CYP2C19 P33261 5/20 0.53
CYP1A2 P05177 4/20 0.53
CYP3A4 P08684 2/20 0.53
TDP1 Q9NUW8 7/20 0.51
HSP90AA1 P07900 4/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8112457 0.88 MEN1 (0.68) MEN1KMT2ASMN1; SMN2MAPTALDH1A1
SCHEMBL27462655 0.86 MEN1 (0.66) MEN1KMT2ASMN1; SMN2MAPTALDH1A1
SCHEMBL11973053 0.85 MEN1 (0.60) MEN1KMT2ASMN1; SMN2MAPTALDH1A1
SCHEMBL14573268 0.85 MEN1 (0.60) MEN1KMT2ASMN1; SMN2MAPTALDH1A1
SCHEMBL8901804 0.82 MEN1 (0.54) MEN1KMT2ASMN1; SMN2MAPTALDH1A1
SCHEMBL11973580 0.81 MEN1 (0.77) MEN1KMT2ASMN1; SMN2MAPTALDH1A1
SCHEMBL24716103 0.79 MAPT (0.78) MEN1KMT2ASMN1; SMN2MAPTALDH1A1
SCHEMBL15322666 0.79 MEN1 (0.64) MEN1KMT2ASMN1; SMN2MAPTALDH1A1
SCHEMBL2246159 0.78 KMT2A (1.00) MEN1KMT2ASMN1; SMN2MAPTALDH1A1
SCHEMBL10700281 0.76 CTSB (0.55) MEN1KMT2ASMN1; SMN2MAPTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-103492028-B Sulfonaminoquinoline hepcidin antagonists 维福(国际)股份公司 2017-02-08 CN disclosed
EP-2675526-B1 NOVEL SULFONAMINOQUINOLINE HEPCIDIN ANTAGONISTS VIFOR (INTERNATIONAL) AG (CH) 2017-02-01 EP disclosed
US-9102688-B2 Sulfonaminoquinoline hepcidin antagonists VIFOR (INTERNATIONAL) AG (CH) 2015-08-11 US disclosed
US-20140364424-A1 Novel Sulfonaminoquinoline Hepcidin Antagonists VIFOR (INTERNATIONAL) AG (CH) 2014-12-11 US disclosed
CN-103492028-A Novel sulfonaminoquinoline hepcidin antagonists VIFOR INT AG 2014-01-01 CN disclosed
EP-2675526-A1 NOVEL SULFONAMINOQUINOLINE HEPCIDIN ANTAGONISTS Vifor (International) AG (CH) 2013-12-25 EP disclosed
WO-2012110603-A1 NOVEL SULFONAMINOQUINOLINE HEPCIDIN ANTAGONISTS VIFOR (INTERNATIONAL) AG (CH) 2012-08-23 WO disclosed
US-20120214803-A1 Novel Sulfonaminoquinoline Hepcidin Antagonists VIFOR (INTERNATIONAL) AG (CH) 2012-08-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120214803-A1 Novel Sulfonaminoquinoline Hepcidin Antagonists HAMP, SLC40A1, FTH1 MEN1 2680/4885KMT2A 3298/4885SMN1; SMN2 4086/4885
US-20140364424-A1 Novel Sulfonaminoquinoline Hepcidin Antagonists HAMP, SLC40A1, FTH1 MEN1 2680/4885KMT2A 3298/4885SMN1; SMN2 4086/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.